机译:患有超细胞症的急性髓性白血病(AML)的新诊断患者(PTS)中的特征,治疗模式和结果:来自大型患者的调查结果
Yale Sch Med Sect Hematol Dept Internal Med New Haven CT USA;
Yale Sch Publ Hlth Dept Biostat New Haven CT USA;
Hosp Univ &
Politecn La Fe Valencia Spain;
St Louis Hop AP HP Hematol Dept Paris France;
Yale Sch Med Sect Hematol Dept Internal Med New Haven CT USA;
Heinrich Heine Univ Dept Hematol Oncol &
Clin Immunol Dusseldorf Germany;
Univ Nebraska Med Ctr Omaha NE USA;
Cleveland Clin Leukemia Program Cleveland OH 44106 USA;
Harvard Med Sch Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Indiana Univ Simon Canc Ctr Indianapolis IN 46204 USA;
Univ Penn Dept Med Div Hematol Oncol Philadelphia PA 19104 USA;
Univ Illinois Chicago IL USA;
Cornell Univ Weill Cornell Med New York NY 10021 USA;
CHU Nice Dept Hematol Clin Nice France;
Hosp Univ &
Politecn La Fe Valencia Spain;
St Louis Hop AP HP Hematol Dept Paris France;
Heinrich Heine Univ Dept Hematol Oncol &
Clin Immunol Dusseldorf Germany;
Univ Nebraska Med Ctr Omaha NE USA;
Cleveland Clin Leukemia Program Cleveland OH 44106 USA;
Harvard Med Sch Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Indiana Univ Simon Canc Ctr Indianapolis IN 46204 USA;
Univ Penn Dept Med Div Hematol Oncol Philadelphia PA 19104 USA;
Cornell Univ Weill Cornell Med New York NY 10021 USA;
Hosp Univ &
Politecn La Fe Valencia Spain;
St Louis Hop AP HP Hematol Dept Paris France;
Hosp Univ &
Politecn La Fe Valencia Spain;
St Louis Hop AP HP Hematol Dept Paris France;
Univ Clin Hosp INCLIVA Valencia Spain;
Hosp Univ &
Politecn La Fe Valencia Spain;
Univ Illinois Chicago IL USA;
Univ Penn Dept Med Div Hematol Oncol Philadelphia PA 19104 USA;
Yale Sch Med Sect Hematol Dept Internal Med New Haven CT USA;
Yale Sch Med Sect Hematol Dept Internal Med New Haven CT USA;
Yale Sch Med Sect Hematol Dept Internal Med New Haven CT USA;
机译:患有超细胞症的急性髓性白血病(AML)的新诊断患者(PTS)中的特征,治疗模式和结果:来自大型患者的调查结果
机译:患有新诊断的急性髓性白血病患者的护理和临床结果模式,呈现出不接受密集化疗的高织益细胞症
机译:新诊断的急性髓性白血病和高织血症患者的结果没有接受密集化疗:大型国际数据库的结果
机译:用于治疗急性髓性白血病(AML)的最佳疾病和患者特异性化疗方案的设计
机译:根据2017年日本成人白血病研究组(JALSG)AML201研究治疗的成人急性髓性白血病患者的遗传学预测,根据2017 ELN风险分层进行预后分析
机译:两次低剂量Gemtuzumab ozogamicin的随机试验作为新诊断的急性髓细胞白血病对老年患者的诱导单一的疗法而不是考虑到密集化疗的候选人。 EITTC和Gimema白血病组的II期研究(AML-19)
机译:高织益菌病在新诊断的急性髓性白血病患者中经历同种异体干细胞移植的长期影响:eBMT急性白血病工作组的分析